Follistatin 344 vs PEG-MGF
A side-by-side research comparison of Follistatin 344 and PEG-MGF across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Follistatin 344 | PEG-MGF |
|---|---|---|
| Full name | Follistatin 344 (FST-344) | PEGylated Mechano Growth Factor |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Research compound |
| Mechanism | Binds myostatin and activin A with high affinity, preventing ActRIIB receptor activation. Removes the brake on muscle growth allowing uninhibited satellite cell proliferation. | PEGylation protects MGF from rapid degradation, extending half-life from minutes to hours. Activates satellite cells systemically for whole-body muscle recovery. |
| Molecular weight | 36,000 Da | ~5000 Da (with PEG) |
| Half-life | 2-4 hours | ~30 minutes to several hours (vs 5-7 min native) |
| Bioavailability | Moderate (SubQ) | ~85% subcutaneous |
| Typical dose | 100-200 mcg | 100-200 mcg |
| Frequency | Daily for 10-30 days | 2-3x per week |
| Route | Subcutaneous | Subcutaneous injection |
Follistatin 344 reported benefits
- Significant muscle growth
- Myostatin inhibition
- Increased strength
- Activin neutralization
- Enhanced recovery
PEG-MGF reported benefits
- Extended half-life vs native MGF
- Systemic satellite cell activation
- Whole-body recovery
- Less frequent dosing
Related comparisons
Research and educational reference only. Not medical advice.